157 related articles for article (PubMed ID: 21422192)
1. Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction.
Nagy LD; Mocny CS; Diffenderfer LE; Hsi DJ; Butler BF; Arthur EJ; Fletke KJ; Palamanda JR; Nomeir AA; Furge LL
Drug Metab Dispos; 2011 Jun; 39(6):974-83. PubMed ID: 21422192
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine.
Palamanda JR; Casciano CN; Norton LA; Clement RP; Favreau LV; Lin C; Nomeir AA
Drug Metab Dispos; 2001 Jun; 29(6):863-7. PubMed ID: 11353755
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators.
Livezey M; Nagy LD; Diffenderfer LE; Arthur EJ; Hsi DJ; Holton JM; Furge LL
Drug Metab Lett; 2012 Mar; 6(1):7-14. PubMed ID: 22372551
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds.
Bolles AK; Fujiwara R; Briggs ED; Nomeir AA; Furge LL
Drug Metab Dispos; 2014 Dec; 42(12):2087-96. PubMed ID: 25273356
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.
Hutzler JM; Steenwyk RC; Smith EB; Walker GS; Wienkers LC
Chem Res Toxicol; 2004 Feb; 17(2):174-84. PubMed ID: 14967005
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics of CYP2D6 polymorphisms in the absence and presence of a mechanism-based inactivator reveals changes in local flexibility and dominant substrate access channels.
de Waal PW; Sunden KF; Furge LL
PLoS One; 2014; 9(10):e108607. PubMed ID: 25286176
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine.
Liu Y; Cui T; Peng Y; Ji M; Zheng J
J Biochem Mol Toxicol; 2019 Feb; 33(2):e22251. PubMed ID: 30368994
[TBL] [Abstract][Full Text] [Related]
9. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
11. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
12. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6.
Kalgutkar AS; Zhou S; Fahmi OA; Taylor TJ
Drug Metab Dispos; 2003 May; 31(5):596-605. PubMed ID: 12695348
[TBL] [Abstract][Full Text] [Related]
13. The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein.
Lin HL; Hollenberg PF
J Pharmacol Exp Ther; 2007 Apr; 321(1):276-87. PubMed ID: 17251390
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
15. Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.
Smith G; Modi S; Pillai I; Lian LY; Sutcliffe MJ; Pritchard MP; Friedberg T; Roberts GC; Wolf CR
Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):783-92. PubMed ID: 9560305
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.
Lin HL; Zhang H; Medower C; Hollenberg PF; Johnson WW
Drug Metab Dispos; 2011 Feb; 39(2):345-50. PubMed ID: 21068193
[TBL] [Abstract][Full Text] [Related]
17. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
Dalmadi B; Leibinger J; Szeberényi S; Borbás T; Farkas S; Szombathelyi Z; Tihanyi K
Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
[TBL] [Abstract][Full Text] [Related]
18. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.
Bonn B; Masimirembwa CM; Castagnoli N
Drug Metab Dispos; 2010 Jan; 38(1):187-99. PubMed ID: 19797609
[TBL] [Abstract][Full Text] [Related]
19. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.
Modi S; Gilham DE; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1997 Apr; 36(15):4461-70. PubMed ID: 9109653
[TBL] [Abstract][Full Text] [Related]
20. Site-Directed Mutagenesis of Cytochrome P450 2D6 and 2C19 Enzymes: Expression and Spectral Characterization of Naturally Occurring Allelic Variants.
Dong AN; Pan Y; Palanisamy UD; Yiap BC; Ahemad N; Ong CE
Appl Biochem Biotechnol; 2018 Sep; 186(1):132-144. PubMed ID: 29524040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]